Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-
mediated immune responses against cancer cells. Immune checkpoint inhibitors have …

The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in
which therapeutic agents are used to target immune cells rather than cancer cells. The first …

Advances in cancer therapy in the past few years include the development of medications
that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and …

Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti
cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has …

Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …